PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES [RAINBOW TRIAL] (NCT06371417)

The RAY902CT study is designed to evaluate the safety and efficacy of RAY121 in adult participants with Bullous Pemphigoid (BP) or Behcet’s syndrome.  Participants receive trial medication via a monthly injection under the skin (subcutaneous). The treatment period will be approximately 12 weeks with the option of a long-term extension.

Trial phase

Phase 1

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Professor Johannes S Kern

Key inclusion data

Aged between 18-85 years of age at screening (BP only)
Have a clinical diagnosis of Bullous Pemphigoid or Behcet’s syndrome
People with Behcet’s syndrome must have had oral ulcers at least 3 times in the last 12 months and at least 2 oral ulcers in the past 4 weeks before screening. 
Have no other autoimmune diseases other than BP or Behcet’s syndrome